Last reviewed · How we verify

Ross D. Zafonte, MD — Portfolio Competitive Intelligence Brief

Ross D. Zafonte, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Levodopa / Carbidopa Levodopa / Carbidopa marketed Dopamine precursor with peripheral decarboxylase inhibitor Aromatic amino acid decarboxylase (AADC); dopamine pathway Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Bial - Portela C S.A. · 1 shared drug class
  3. IRCCS San Raffaele Roma · 1 shared drug class
  4. Intec Pharma Ltd. · 1 shared drug class
  5. NeuroDerm Ltd. · 1 shared drug class
  6. Pfizer · 1 shared drug class
  7. University of Buenos Aires · 1 shared drug class
  8. XenoPort, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ross D. Zafonte, MD:

Cite this brief

Drug Landscape (2026). Ross D. Zafonte, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ross-d-zafonte-md. Accessed 2026-05-17.

Related